Amgen (AMGN) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Amgen Inc (AMGN) 3-Minute Overview ## 🎯 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Amgen is a biotech giant that makes complex biologic drugs for serious diseases like cancer and arthritis, earning steady profits from a portfolio of established blockbusters while betting big on newer pipeline drugs to fuel its next growth phase. > **📍 Basic Profile** > > Market Cap **$212 billion** · Biotechnology · NASDAQ · Price **$393.10** --- > **⚡ 3 Things You Should Know** > > 1. 💰 **Profit Machine with Sticky Products:** Gross margins of 74% and net margins of 21% are excellent for a drugmaker. Its drugs treat chronic conditions (arthritis, osteoporosis), creating recurring revenue that's hard to disrupt. > > 2. 📉 **Growth is Slowing, but Beating Expectations:** Revenue growth over 3 years (11.8%) and 5 years (7.7%) is decent, but EPS growth has been much slower (5.5% over 3 years, 2.9% over 5 years). The good news? The company has beaten earnings estimates by 6-12% for four straight quarters. > > 3. ⚠️ **High Leverage is the Elephant in the Room:** Debt-to-equity is a staggering 631%. This is largely from the $28 billion Horizon Therapeutics acquisition. While cash flow is solid, this high leverage makes the stock more sensitive to interest rates and any earnings hiccups. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Strong💪 | Net margin 21%, among the best in biotech | > | Growth Rate | Slow🐢 | Revenue growth ~8% over 5 years, EPS growth lagging | > | Financial Health | Tight🧡 | Debt-to-equity of 631% is very high | > | Valuation | Fair | PE of 27x is reasonable for a steady biotech | --- ## 📋 2-Minute Deep Dive ### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Sells patented biologic drugs (injectable/infusion treatments) to hospitals, clinics, and pharmacies for chronic and serious diseases, making money through high-margin, recurring prescriptions. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Established Products (Enbrel, Prolia, etc.) | ~60% | → | The cash cows, but facing biosimilar competition | | Newer/Oncology Portfolio (Lumakras, Blincyto, etc.) | ~25% | ↑ | Growth driver, especially from Horizon acquisition | | Biosimilars | ~15% | ↑ | Growing, but lower margin than original biologics | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 73.95% | Excellent | High R&D costs are already baked in; once a drug is approved, production is cheap | | Net Margin | 20.96% | Excellent | Keeps about $0.21 of every dollar earned after all expenses | | ROE | 89.41% | Exceptional | This is inflated by high debt; ROA (8.5%) gives a clearer picture of asset efficiency | --- ### 📈 How's the Growth? **Growth Assessment:** Steady but Slowing | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth (3Y) | 11.77% | N/A | Steady, driven by acquisitions | | EPS Growth (3Y) | 5.51% | N/A | Slowing, as higher interest costs eat into profits | **Growth Quality:** > The growth is real but not entirely organic. A significant chunk comes from the Horizon acquisition (which added rare disease drugs like Tepezza). Organic growth from existing products is modest, as older drugs like Enbrel face pricing pressure and biosimilar competition. The company's future growth depends heavily on its pipeline. --- ### 💰 Financial Health Check **One Sentence:** Think of a person who just bought a very expensive house with a big mortgage—they have a great job and solid income, but the monthly payments are a real burden. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 631% | <60% safe | 🚨 Very High | | Current Ratio | 1.26 | >1.5 healthy | ⚠️ Tight | | Cash Flow (per share) | $20.77 | >0 | ✅ Strong | **The Key Insight:** The high debt is the single biggest risk. Amgen took on massive debt to buy Horizon. While its operating cash flow ($20.77/share) is strong enough to cover interest payments (interest coverage of 12.7x is healthy), this leverage limits financial flexibility. A recession or a major drug failure could make debt servicing painful. --- ### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $269.77 - 52-Week High: $398.00 - Current: $393.10, **Very close to the high** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | | ●(97% position) | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 27.3x | 5-year avg ~18-20x | Pricey by ~35-50% | | vs Peers | PE 27.3x | Industry avg ~25-30x | Fair | **What the Current Valuation is Betting On:** > At a 52-week high and a PE well above its own historical average, the market is betting that: (1) the Horizon acquisition will deliver strong revenue and cost synergies, (2) new pipeline drugs (like the obesity candidate MariTide) will be major blockbusters, and (3) the company can successfully navigate biosimilar competition. If these bets don't pay off, the stock could be vulnerable to a correction. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | Jul 2026 | Earnings Preview: Q2 earnings expected to decline | Negative – Sets a low bar; a beat would be a positive surprise | | Jul 2026 | Stock showing technical strength and breakout setup | Neutral – Technicals look good, but fundamentals matter more | | Jun 2026 | Court blocks Colorado price cap on Enbrel | Positive – Removes a major regulatory overhang for a key drug | | Jun 2026 | Amgen beating estimates for 4 straight quarters | Positive – Shows operational execution is strong | --- ## 📊 Want More? 3-Minute Complete Analysis ### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 73.95% | ~74% | ~73% | → Stable | | Net Margin | 20.96% | ~22% | ~24% | ↓ Slightly declining | | ROE | 89.41% | ~85% | ~70% | ↑ Rising (but due to more debt) | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | ~12% | ~10% | ~5% | ↑ Improving (acquisitions help) | | Profit Growth | ~6% | ~8% | ~10% | ↓ Slowing | | EPS Growth | ~5.5% | ~7% | ~9% | ↓ Slowing | --- ### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | Q1 2026 | $4.85 | $5.15 | +6.1% Beat 😀 | | Q4 2025 | $4.83 | $5.29 | +9.6% Beat 😀 | | Q3 2025 | $5.11 | $5.64 | +10.3% Beat 😀 | | Q2 2025 | $5.39 | $6.02 | +11.6% Beat 😀 | **Earnings Trend Interpretation:** This is a four-quarter streak of solid beats, with the surprise percentage actually accelerating. This suggests management is conservative with guidance, and the business is more resilient than Wall Street expects. It's a positive signal for operational quality. --- ### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 21 firms | 49% | | Hold | 19 firms | 44% | | Sell | 3 firms | 7% | **Target Price:** N/A (Data unavailable) **vs Current Price:** N/A **Insider Activity:** Net **buying** of ~$665k in May 2026 via stock awards (grants, not open market purchases) > **What this means:** These are stock grants to directors and executives, not voluntary open-market buys. It's a neutral signal. They aren't selling, which is mildly positive, but they aren't putting their own money in either. --- ### IV. Key Risk Alerts **3 Risks to Watch:** 1. **🚨 Debt Overhang:** Debt-to-equity of 631% is the highest among major biotech peers. If interest rates stay high or earnings dip, debt servicing could become a major drag on profitability and stock price. 2. **🩺 Pipeline Dependency:** The stock's high valuation is betting on new drugs (MariTide for obesity, Horizon drugs for rare diseases). If clinical trials fail or drugs don't meet sales expectations, the stock could fall hard. 3. **💊 Biosimilar Competition:** Older blockbusters like Enbrel and Neulasta are losing patent protection. Cheaper biosimilars are eating into market share, which will pressure revenue growth over the next 3-5 years. --- ## 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** A mature biotech giant with a fortress of profitable drugs, but a heavy debt load from a large acquisition. > > **Key strength:** Incredible profitability (74% gross margins, 21% net margins) and a track record of beating earnings estimates. > > **Key risk:** The massive debt (631% debt-to-equity) and dependence on a pipeline of unproven drugs to justify the current high valuation. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis